Kevin Jong, MD
Ophthalmology · Houston, TXNPI 1124013214
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,579 of the $17,031 with a category attached, or 68.0%. It is spread thinly across 26 manufacturers, the largest accounting for just 23.5%. Reporting peaked in 2020 at $4,705 and has fallen 54.0% since, to $2,165 in 2025. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 395 payments — averaging $43.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch Health US, LLC$4K
- AbbVie$4K
- Alcon$2K
- Bausch & Lomb Americas Inc.$1K
- Johnson & Johnson Surgical Vision, Inc.$1K
- Tarsus Pharmaceuticals, Inc.$772
- plus $4K from 20 others
Across 1,491 payments — averaging $914.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$1.1M
- Bausch Health US, LLC$241K
- Bausch & Lomb Americas Inc.$39K
- Shire North American Group Inc$8K
- Amneal Pharmaceuticals LLC$7K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
What the payments were for
- Consulting fees$5,33531%
- Speaking & faculty fees$1001%
- Food & beverage$11,57968%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch Health US, LLC | 1 | $4,000 |
| AbbVie(2 entities) | 129 | $3,585 |
| Alcon | 49 | $2,031 |
| Bausch & Lomb Americas Inc. | 47 | $1,465 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $1,405 |
| Tarsus Pharmaceuticals, Inc. | 27 | $772 |
| Novartis | 33 | $698 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 20 | $611 |
| Aerie Pharmaceuticals, Inc. | 11 | $517 |
| Sun Pharmaceutical Industries Inc. | 22 | $415 |
| Eyevance Pharmaceuticals LLC | 18 | $361 |
| Glaukos Corporation | 5 | $358 |
| Rxsight Inc | 2 | $142 |
| Thea Pharma Inc. | 5 | $125 |
| Oyster Point Pharma, Inc. | 5 | $124 |
| Carl Zeiss Meditec USA, Inc. | 3 | $121 |
| Sight Sciences, Inc. | 3 | $69 |
| Harrow Eye, LLC | 2 | $61 |
| Kala Pharmaceuticals, Inc. | 2 | $39 |
| Dompe US, Inc. | 1 | $29 |
| Mallinckrodt Enterprises LLC | 1 | $23 |
| NEW World Medical,inc. | 1 | $18 |
| Amgen | 1 | $17 |
| Ocular Therapeutix, Inc. | 1 | $17 |
| Carl Zeiss Meditec, Inc. | 1 | $14 |
| Akorn, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CVISC50$4,000
- Rocklatan$503
- enVista MX60 IOL$409
- VUITY$372
- Rhopressa$362
- XEN GLAUCOMA TREATMENT SYSTEM$355
- Clareon$274
- LenSx$269
- XEN$225
- ENVISTA ENVY IOL$152
- PanOptix$150
- Clareon PanOptix Pro$148
- Zerviate$134
- RXSIGHT CONTACT LENS$127
- RXSIGHT INJECTOR CARTRIDGE$127
- RXSIGHT INJECTOR HANDPIECE$127
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$127
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$127
- MIEBO$125
- DURYSTA$125
How this compares
$17,031 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 718 | $337,472 |
| XiidraLifitegrast | 191 | $156,508 |
| VyzultaLatanoprostene Bunod | 289 | $107,658 |
| RestasisCyclosporine | 81 | $69,398 |
| CombiganBrimonidine Tartrate/Timolol | 125 | $48,321 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 207 | $44,105 |
| RocklatanNetarsudil Mesylat/Latanoprost | 95 | $39,955 |
| XdemvyLotilaner | 18 | $34,184 |
| RhopressaNetarsudil Mesylate | 72 | $28,101 |
| Latanoprost | 2,799 | $26,593 |
| Alphagan PBrimonidine Tartrate | 70 | $25,788 |
| Prednisolone Acetate | 841 | $21,392 |
| Brinzolamide | 118 | $17,738 |
| Travoprost | 99 | $14,519 |
| ProlensaBromfenac Sodium | 27 | $11,552 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $3,585 | $480,980994 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $1,465 | $264,166480 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $517 | $68,056167 claims |
| AlconSimbrinza | $2,031 | $44,105207 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $772 | $34,18418 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm | $611 | $15,30942 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $124 | $9,15612 claims |
| Akorn, Inc.Betimol | $13 | $2,15913 claims |
| Eyevance Pharmaceuticals LLCFlarex | $361 | $1,88414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Houston
- John MichelettiHouston$916K
- Christina WengHouston$676K
- Peter ChangHouston$656K
- Zaina Al-MohtasebHouston$636K
- Stephen SladeHouston$530K
- David BrownHouston$514K
- Shaheen KavoussiHouston$480K
- Elvia CansecoHouston$322K
- Bac NguyenHouston$319K
- Douglas KochHouston$308K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.